Your browser doesn't support javascript.
Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity.
Stankiewicz Karita, Helen C; Dong, Tracy Q; Johnston, Christine; Neuzil, Kathleen M; Paasche-Orlow, Michael K; Kissinger, Patricia J; Bershteyn, Anna; Thorpe, Lorna E; Deming, Meagan; Kottkamp, Angelica; Laufer, Miriam; Landovitz, Raphael J; Luk, Alfred; Hoffman, Risa; Roychoudhury, Pavitra; Magaret, Craig A; Greninger, Alexander L; Huang, Meei-Li; Jerome, Keith R; Wener, Mark; Celum, Connie; Chu, Helen Y; Baeten, Jared M; Wald, Anna; Barnabas, Ruanne V; Brown, Elizabeth R.
  • Stankiewicz Karita HC; Division of Allergy and Infectious Diseases, University of Washington, Seattle.
  • Dong TQ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Johnston C; Division of Allergy and Infectious Diseases, University of Washington, Seattle.
  • Neuzil KM; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Paasche-Orlow MK; Department of Laboratory Medicine and Pathology, University of Washington, Seattle.
  • Kissinger PJ; Department of Medicine, University of Maryland School of Medicine, Baltimore.
  • Bershteyn A; Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
  • Thorpe LE; Department of Medicine, Boston Medical Center, Boston, Massachusetts.
  • Deming M; Department of Epidemiology, Tulane University, New Orleans, Louisiana.
  • Kottkamp A; Department of Population Health, New York University Grossman School of Medicine, New York.
  • Laufer M; Department of Population Health, New York University Grossman School of Medicine, New York.
  • Landovitz RJ; Department of Medicine, University of Maryland School of Medicine, Baltimore.
  • Luk A; Department of Medicine, New York University Grossman School of Medicine, New York.
  • Hoffman R; Department of Medicine, University of Maryland School of Medicine, Baltimore.
  • Roychoudhury P; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore.
  • Magaret CA; Department of Medicine, University of California, Los Angeles, Los Angeles.
  • Greninger AL; Department of Medicine, Tulane University, New Orleans, Louisiana.
  • Huang ML; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore.
  • Jerome KR; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Wener M; Department of Laboratory Medicine and Pathology, University of Washington, Seattle.
  • Celum C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Chu HY; Department of Laboratory Medicine and Pathology, University of Washington, Seattle.
  • Baeten JM; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Wald A; Department of Laboratory Medicine and Pathology, University of Washington, Seattle.
  • Barnabas RV; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Brown ER; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
JAMA Netw Open ; 5(1): e2142796, 2022 01 04.
Article in English | MEDLINE | ID: covidwho-1615909
ABSTRACT
Importance The SARS-CoV-2 viral trajectory has not been well characterized in incident infections. These data are needed to inform natural history, prevention practices, and therapeutic development.

Objective:

To characterize early SARS-CoV-2 viral RNA load (hereafter referred to as viral load) in individuals with incident infections in association with COVID-19 symptom onset and severity. Design, Setting, and

Participants:

This prospective cohort study was a secondary data analysis of a remotely conducted study that enrolled 829 asymptomatic community-based participants recently exposed (<96 hours) to persons with SARS-CoV-2 from 41 US states from March 31 to August 21, 2020. Two cohorts were studied (1) participants who were SARS-CoV-2 negative at baseline and tested positive during study follow-up, and (2) participants who had 2 or more positive swabs during follow-up, regardless of the initial (baseline) swab result. Participants collected daily midturbinate swab samples for SARS-CoV-2 RNA detection and maintained symptom diaries for 14 days. Exposure Laboratory-confirmed SARS-CoV-2 infection. Main Outcomes and

Measures:

The observed SARS-CoV-2 viral load among incident infections was summarized, and piecewise linear mixed-effects models were used to estimate the characteristics of viral trajectories in association with COVID-19 symptom onset and severity.

Results:

A total of 97 participants (55 women [57%]; median age, 37 years [IQR, 27-52 years]) developed incident infections during follow-up. Forty-two participants (43%) had viral shedding for 1 day (median peak viral load cycle threshold [Ct] value, 38.5 [95% CI, 38.3-39.0]), 18 (19%) for 2 to 6 days (median Ct value, 36.7 [95% CI, 30.2-38.1]), and 31 (32%) for 7 days or more (median Ct value, 18.3 [95% CI, 17.4-22.0]). The cycle threshold value has an inverse association with viral load. Six participants (6%) had 1 to 6 days of viral shedding with censored duration. The peak mean (SD) viral load was observed on day 3 of shedding (Ct value, 33.8 [95% CI, 31.9-35.6]). Based on the statistical models fitted to 129 participants (60 men [47%]; median age, 38 years [IQR, 25-54 years]) with 2 or more SARS-CoV-2-positive swab samples, persons reporting moderate or severe symptoms tended to have a higher peak mean viral load than those who were asymptomatic (Ct value, 23.3 [95% CI, 22.6-24.0] vs 30.7 [95% CI, 29.8-31.4]). Mild symptoms generally started within 1 day of peak viral load, and moderate or severe symptoms 2 days after peak viral load. All 535 sequenced samples detected the G614 variant (Wuhan strain). Conclusions and Relevance This cohort study suggests that having incident SARS-CoV-2 G614 infection was associated with a rapid viral load peak followed by slower decay. COVID-19 symptom onset generally coincided with peak viral load, which correlated positively with symptom severity. This longitudinal evaluation of the SARS-CoV-2 G614 with frequent molecular testing serves as a reference for comparing emergent viral lineages to inform clinical trial designs and public health strategies to contain the spread of the virus.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Severity of Illness Index / RNA, Viral / Virus Shedding / Viral Load / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Variants Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: JAMA Netw Open Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Severity of Illness Index / RNA, Viral / Virus Shedding / Viral Load / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Variants Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: JAMA Netw Open Year: 2022 Document Type: Article